On October 10, 2020 3D Medicines, a Beijing clinical-stage biopharma, reported that it completed a $225 million funding (Press release, 3D Medicines, OCT 19, 2020, View Source [SID1234568664]). Two years ago, 3DMed spun off its diagnostics business into 3D Diagnostics and now concentrates on development of immunotherapy drugs. In 2017, 3DMed agreed to conduct the clinical trials and commercialization of Alphamab’s envafolimab (KN035), a subcutaneous injection PD-L1 checkpoint inhibitor. The candidate has started clinical trials in China, the US and Japan. The company’s funding was co-led by China Capital Management and Efung Capital, a biomedical venture capital firm.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!